– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome –
– KOMET-001 study to resume screening and enrollment of new patients –
Read more at globenewswire.comKura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.